Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Prototype · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Negative Control | PLACEBO_COMPARATOR | Regular Toothpaste |
| Positive Control | ACTIVE_COMPARATOR | Standard anti-plaque and anti-bacterial toothpaste. |
| Prototype | ACTIVE_COMPARATOR | AN0128 Toothpaste |
| Name | Type | Description |
|---|---|---|
| Negative Control (Regular Toothpaste) | OTHER | Regular Toothpaste |
| Positive Control (anti-plaque/anti-bacterial toothpaste) | OTHER | Standard anti-plaque and anti-bacterial toothpaste |
| Prototype (AN0128 Toothpaste) | DRUG | AN0128 Toothpaste |
Inclusion Criteria: * Must be between ages 18 to 65 years inclusive * Have a minimum of 16 natural uncrowned teeth (excluding 3rd molars) present * Must give written informed consent * Be in good general health * Must discontinue oral hygiene for 24-hours after initial appointment * No known histor...
Prototype is an investigational small molecule being developed for the treatment of dental plaque. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Prototype is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting clinical trials to evaluate the drug's safety and efficacy in treating dental plaque.
Prototype is in Phase 1 clinical development. It is an investigational drug and has not yet been approved for commercial use. The drug is being studied for its potential to treat dental plaque.
Prototype has one completed Phase 1 clinical trial, NCT00762151, titled "A Study to Investigate the Anti-Plaque Effect of AN0128 Toothpaste." The trial enrolled 18 participants in the United States and was placebo-controlled.
Prototype is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for dental plaque. The drug has not yet completed the clinical trials required for regulatory approval.